Acromegaly when secretions of growth hormone & insulin-like growth factor-1 remain abnormal after surgery &/or RT, clinical symptoms associated w/ acromegaly & neuroendocrine (particularly carcinoid) tumours. 120 mg: Grade 1 & subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded in adults w/ unresectable locally advanced or metastatic disease.
Acromegaly & carcinoid tumours Initially 60-120 mg deep SC inj every 28 days, may be increased/decreased depending on patient's response. GEP-NETs 120 mg as single deep SC inj every 28 days continued as long as needed.
Discontinue use if cholelithiasis complications are suspected. Patients w/ bradycardia, preexisting cardiac disorders; steatorrhoea. Monitor blood glucose levels; pituitary tumour vol in patients w/ adenomas. Perform gallbladder echography prior to, during & every 6 mth of treatment; thyroid function test during therapy. May affect ability to drive & use machines. May affect female fertility. Avoid use during pregnancy. Not to be used during lactation. Childn & adolescents.
Sign Out
 120 mg091ddf13-e11b-470e-bf9b-ac4400bb5b78.GIF)
